Voro Therapeutics and Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Gen Tumor-Activated ADCs
“Unlocking the full potential of highly potent payloads requires a new level of control over where and when activation occurs,” said Ugur Eskiocak, PhD, Co-Founder and CEO of Voro Therapeutics. “PrimeBody is designed to potentially provide that level of control through tumor-selective activation and expand the target universe to include antigens historically considered too broadly expressed. We believe this approach has the potential to fundamentally expand the therapeutic index of ADCs. We are excited to collaborate with Daiichi Sankyo, a global leader in ADC innovation with a proven track record of developing transformative medicines for patients.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.